MedCity News January 9, 2026
Aktis Oncology’s IPO will support a pipeline of “miniprotein” radioconjugates that could offer advantages over other targeted radiation cancer treatments. In addition to its internal pipeline, Aktis has a discovery partnership with Eli Lilly.
For all of the benefit that radiopharmaceuticals offer, these treatments currently address a limited number of cancer targets. Aktis Oncology has technology that could broaden the reach of this type of therapy, potentially addressing more targets to help more patients. The clinical-stage company now has $318 million in IPO cash to support development of its pipeline.
Following a lackluster 2025 that saw limited biotech IPO activity, Aktis found sufficient investor interest to boost the size of its deal to 17.65 million shares, up from the 11.77...
Today's Sponsors
Today's Sponsor